To include your compound in the COVID-19 Resource Center, submit it here.

Altheos Mines its Rho-lodex

Newco Altheos wins deal for glaucoma compounds from Japanese pharma Asahi Kasei

After concluding that all the interesting new projects in the U.S. and Europe had been picked over, the founders of Altheos Inc. turned to Asia to find assets for in-licensing. Based on the strength of their relationships with Asahi Kasei Pharmaceutical Corp., their experience with ophthalmic products and their willingness to forgo other projects they'd been evaluating, they were able to secure rights to what they believe to be best-in-class topical Rho kinase inhibitors for glaucoma.

Altheos also closed a $20 million

Read the full 810 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE